The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Hello TELLOMAK: new trial for T-cell lymphoma
Pierluigi Porcu, MD, Sidney Kimmel Cancer Center – Jefferson Health, Philadelphia, PA, discusses the current open-label, multicohort, multi-center, international Phase II TELLOMAK trial (NCT03902184), evaluating the anti-KIR3DL2 agent IPH4102 alone or with chemotherapy in advanced T-cell lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
